Free Trial Information
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...an NDA submission planned for the androgen receptor agonist this year. TwinStrand closes A round TwinStrand...
...seed round in 2018 (see “Sequoia China Leads Seed Round” ). BioCentury Staff Deep Genomics Inc. Kintor Pharmaceuticals Ltd. TwinStrand IPO...
Read More
BioCentury | Aug 1, 2005
Clinical News

TST10088: Phase I start

...Twinstrand will begin next month a dose-escalation, U.S. Phase I trial in 40 patients. Twinstrand Therapeutics Inc....
Read More
BioCentury | Apr 28, 2003
Company News

Cangene, Twinstrand deal

...chemical, biological, radiological or nuclear incidents) Research and Technology Initiative. Cangene Corp. (TSE:CNJ), Toronto, Ontario Twinstrand Therapeutics Inc....
Read More
Items per page:
1 - 3 of 3
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...an NDA submission planned for the androgen receptor agonist this year. TwinStrand closes A round TwinStrand...
...seed round in 2018 (see “Sequoia China Leads Seed Round” ). BioCentury Staff Deep Genomics Inc. Kintor Pharmaceuticals Ltd. TwinStrand IPO...
Read More
BioCentury | Aug 1, 2005
Clinical News

TST10088: Phase I start

...Twinstrand will begin next month a dose-escalation, U.S. Phase I trial in 40 patients. Twinstrand Therapeutics Inc....
Read More
BioCentury | Apr 28, 2003
Company News

Cangene, Twinstrand deal

...chemical, biological, radiological or nuclear incidents) Research and Technology Initiative. Cangene Corp. (TSE:CNJ), Toronto, Ontario Twinstrand Therapeutics Inc....
Read More
Items per page:
1 - 3 of 3